Literature DB >> 19940786

Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats.

Agnieszka Walkowska1, Petra Skaroupková, Zuzana Husková, Zdenka Vanourková, Vera Certíková Chábová, Vladimír Tesar, Herbert J Kramer, John R Falck, John D Imig, Elzbieta Kompanowska-Jezierska, Janusz Sadowski, Ludek Cervenka.   

Abstract

OBJECTIVE: The contribution of epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) as cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip (2K1C) Goldblatt hypertensive rats was investigated during the phases of initial and stable hypertension, that is, 7 or 27 days after clipping, respectively.
METHODS: Male Hannover Sprague-Dawley rats had the right renal artery clipped or underwent sham operation. Urinary excretion of EETs, their inactive metabolites dihydroxyeicosatrienoic acids and of 20-HETE was measured. Intrarenal cytochrome P-450 protein expression and the activities of epoxygenase, omega-hydroxylase and soluble epoxide hydrolase were also determined. The responses of renal hemodynamics and electrolyte excretion of the nonclipped kidney to left renal artery infusions of inhibitors of EETs or 20-HETE formation (MS-PPOH and DDMS, respectively) were measured.
RESULTS: In 2K1C rats, urinary excretion of EETs was significantly lower and that of 20-HETE was higher than that in sham-operated animals only on day 27 after clipping. Intrarenal inhibition of EETs significantly decreased renal hemodynamics and sodium excretion in sham-operated but not in 2K1C rats. Intrarenal inhibition of 20-HETE decreased sodium excretion in sham-operated rats but elicited increases in renal hemodynamics and sodium excretion in 2K1C rats.
CONCLUSION: Our results indicate that the nonclipped kidney of Goldblatt 2K1C rats in the phase of sustained hypertension exhibits decreased intrarenal EETs and elevated 20-HETE levels as compared with the kidney of sham-operated animals. This suggests that altered production and action of cytochrome P-450-derived metabolites during this stable phase contributes to the mechanism of Goldblatt 2K1C hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19940786      PMCID: PMC2855337          DOI: 10.1097/HJH.0b013e328334dfd4

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  44 in total

1.  Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids.

Authors:  Z Yu; F Xu; L M Huse; C Morisseau; A J Draper; J W Newman; C Parker; L Graham; M M Engler; B D Hammock; D C Zeldin; D L Kroetz
Journal:  Circ Res       Date:  2000-11-24       Impact factor: 17.367

2.  An orally active epoxide hydrolase inhibitor lowers blood pressure and provides renal protection in salt-sensitive hypertension.

Authors:  John D Imig; Xueying Zhao; Constantine Z Zaharis; Jeffrey J Olearczyk; David M Pollock; John W Newman; In-Hae Kim; Takaho Watanabe; Bruce D Hammock
Journal:  Hypertension       Date:  2005-09-12       Impact factor: 10.190

3.  Cytochrome P450 and cyclooxygenase metabolites contribute to the endothelin-1 afferent arteriolar vasoconstrictor and calcium responses.

Authors:  J D Imig; B T Pham; E A LeBlanc; K M Reddy; J R Falck; E W Inscho
Journal:  Hypertension       Date:  2000-01       Impact factor: 10.190

4.  20-HETE is an endogenous inhibitor of the large-conductance Ca(2+)-activated K+ channel in renal arterioles.

Authors:  A P Zou; J T Fleming; J R Falck; E R Jacobs; D Gebremedhin; D R Harder; R J Roman
Journal:  Am J Physiol       Date:  1996-01

5.  Unraveling the Mystery of Goldblatt Hypertension.

Authors:  L. Gabriel Navar; Lixian Zou; Annette Von Thun; Chi Tarng Wang; John D. Imig; Kenneth D. Mitchell
Journal:  News Physiol Sci       Date:  1998-08

6.  Angiotensin II-induced hypertension: contribution of Ras GTPase/Mitogen-activated protein kinase and cytochrome P450 metabolites.

Authors:  M M Muthalif; N A Karzoun; L Gaber; Z Khandekar; I F Benter; A E Saeed; J H Parmentier; A Estes; K U Malik
Journal:  Hypertension       Date:  2000-10       Impact factor: 10.190

Review 7.  P-450 metabolites of arachidonic acid in the control of cardiovascular function.

Authors:  Richard J Roman
Journal:  Physiol Rev       Date:  2002-01       Impact factor: 37.312

8.  Angiotensin and angiotensin converting enzyme tissue levels in two-kidney, one clip hypertensive rats.

Authors:  S Guan; J Fox; K D Mitchell; L G Navar
Journal:  Hypertension       Date:  1992-12       Impact factor: 10.190

9.  Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors.

Authors:  W B Campbell; D Gebremedhin; P F Pratt; D R Harder
Journal:  Circ Res       Date:  1996-03       Impact factor: 17.367

10.  Pivotal role of angiotensin II receptor subtype 1A in the development of two-kidney, one-clip hypertension: study in angiotensin II receptor subtype 1A knockout mice.

Authors:  Ludek Cervenka; Ivana Vanecková; Zuzana Husková; Zdenka Vanourková; Michaela Erbanová; Monika Thumová; Petra Skaroupková; Martin Opocenský; Jan Malý; Vera Certíková Chábová; Vladimír Tesar; Marcela Bürgelová; Ondrej Viklický; Vladimír Teplan; Michal Zelízko; Herbert J Kramer; L Gabriel Navar
Journal:  J Hypertens       Date:  2008-07       Impact factor: 4.844

View more
  8 in total

1.  Role of cytochrome P-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats.

Authors:  Alexandra Sporková; Libor Kopkan; Sárka Varcabová; Zuzana Husková; Sung Hee Hwang; Bruce D Hammock; John D Imig; Herbert J Kramer; Ludek Cervenka
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-03-16       Impact factor: 3.619

2.  Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension.

Authors:  Jan Neckář; Libor Kopkan; Zuzana Husková; František Kolář; František Papoušek; Herbert J Kramer; Sung Hee Hwang; Bruce D Hammock; John D Imig; Jiří Malý; Ivan Netuka; Bohuslav Ošťádal; Luděk Červenka
Journal:  Clin Sci (Lond)       Date:  2012-06       Impact factor: 6.124

3.  Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system.

Authors:  Sarka Varcabova; Zuzana Huskova; Herbert J Kramer; Sung Hee Hwang; Bruce D Hammock; John D Imig; Kento Kitada; Ludek Cervenka
Journal:  Clin Exp Pharmacol Physiol       Date:  2013-04       Impact factor: 2.557

Review 4.  Soluble epoxide hydrolase: gene structure, expression and deletion.

Authors:  Todd R Harris; Bruce D Hammock
Journal:  Gene       Date:  2013-05-20       Impact factor: 3.688

5.  Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Rats' Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids.

Authors:  Alexandra Sporková; Rami N Reddy; John R Falck; John D Imig; Libor Kopkan; Janusz Sadowski; Luděk Červenka
Journal:  Am J Med Sci       Date:  2016-02-23       Impact factor: 2.378

6.  Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension.

Authors:  Libor Kopkan; Zuzana Husková; Alexandra Sporková; Šárka Varcabová; Zuzana Honetschlägerová; Sung Hee Hwang; Hsing-Ju Tsai; Bruce D Hammock; John D Imig; Herbert J Kramer; Marcela Bürgelová; Alžběta Vojtíšková; Petr Kujal; Zdenka Vernerová; Luděk Červenka
Journal:  Kidney Blood Press Res       Date:  2012-08-29       Impact factor: 2.687

7.  Contribution of selected vasoactive systems to blood pressure regulation in two models of chronic kidney disease.

Authors:  N Drábková; S Hojná; J Zicha; I Vaněčková
Journal:  Physiol Res       Date:  2020-05-29       Impact factor: 1.881

Review 8.  Inhibition of Soluble Epoxide Hydrolase for Renal Health.

Authors:  Jun-Yan Liu
Journal:  Front Pharmacol       Date:  2019-01-10       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.